{"product_id":"enzyme-inhibition-in-drug-discovery-and-development-isbn-9780470281741","title":"Enzyme Inhibition in Drug Discovery and Development","description":"The science and applied approaches of enzyme inhibition in drug discovery and development  \u003cp\u003eOffering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, \u003ci\u003eEnzyme Inhibition in Drug Discovery and Development\u003c\/i\u003e examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.\u003c\/p\u003e \u003cp\u003eWith chapters written by over fifty leading experts in their fields, \u003ci\u003eEnzyme Inhibition in Drug Discovery and Development\u003c\/i\u003e fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the \"good\" inhibitions—desirable pharmacological effects—and \"bad\" inhibitions—drug–drug interactions and toxicity. The book discusses:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eThe drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThrough this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.\u003c\/p\u003e  PREFACE.  \u003cp\u003eCONTRIBUTORS.\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART I. DRUG DISCOVERY APPROACHES AND TECHNOLOGIES.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e1. The Drug Discovery Process (\u003ci\u003eGerald T. Miwa\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e2. Medicinal Chemistry of the Optimization of Enzyme Inhibitors (\u003ci\u003eGeraldine Harriman, Amy Elder, and Indranath Ghosh\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e3. Bioanalytical Technologies in Drug Discovery (\u003ci\u003eJing-Tao Wu\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e4. Safety Biomarkers in Drug Development: Emerging Trends and Implications (\u003ci\u003eEric R. Fedyk\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e5. The Role of Drug Metabolism in Drug Discovery (\u003ci\u003eTonika Bohnert and Liang-Shang Gan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e6. Applied Pharmacokinetics in Drug Discovery and Development (\u003ci\u003eHua Yang, Xingrong Liu, Anjaneya Chimalakonda, Zheng Lu, Cuiping Chen, Frank Lee, and Wen Chyi Shyu\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART II. INHIBITION OF THE DRUG METABOLIZING ENZYMES—THE UNDESIRABLE INHIBITION.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e7. Enzyme Inhibition and Inactivation: Cytochrome P450 Enzymes (\u003ci\u003eR. Scott Obach\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e8. Cytochrome P450 Induction (\u003ci\u003eEdward L. LeCluyse, Michael W. Sinz, Nicola Hewitt, Stephen S. Ferguson, and Jasminder Sahi\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e9. Inhibition of Drug-Metabolizing Enzymes in Gastrointestinal Tract and Its Influence on the Drug–Drug Interaction Prediction (\u003ci\u003eAleksandra Galetin and J. Brian Houston\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e10. Enzyme Inhibition in Various \u003ci\u003eIn Vitro\u003c\/i\u003e Systems (\u003ci\u003ePing Zhou\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e11. Cytochrome P450 Degradation and Its Clinical Relevance (\u003ci\u003eMingxiang Liao, Ping Kang, Bernard P. Murray, and Maria Almira Correia\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e12. Complexities of Working with UDP-Glucuronosyltransferases (UGTs): Focus on Enzyme Inhibition (\u003ci\u003eMichael B. Fisher\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e13. Evaluation of Inhibitors of Drug Metabolism in Human Hepatocytes (\u003ci\u003eAlbert P. Li and Chuang Lu\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e14. Grapefruit Juice and Its Constituents as New Esterase Inhibitors (\u003ci\u003eSuresh K. Balani\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e15. Transporter–Xenobiotic Interactions: An Important Aspect of Drug Development Studies (\u003ci\u003eGang Luo, Richard Ridgewell, and Thomas Guenthner\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e16. Polymorphisms of Drug Transporters and Their Clinical Implications (\u003ci\u003eCindy Q. Xia and Johnny J. Yang\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e17. Clinical Drug Interactions Due to Metabolic Inhibition: Prediction, Assessment, and Interpretation (\u003ci\u003eLisa L. von Moltke and David J. Greenblatt\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e18. Predicting Interindividual Variability of Metabolic Drug–Drug Interactions: Identifying the Causes and Accounting for Them Using Systems Approach (\u003ci\u003eAmin Rostami-Hodjegan\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e\u003cb\u003ePART III. INHIBITION OF THE DRUG TARGET ENZYMES—THE DESIRABLE INHIBITION.\u003c\/b\u003e\u003c\/p\u003e \u003cp\u003e19. NF-κB: Mechanism, Tumor Biology, and Inhibitors (\u003ci\u003eLenny Dang\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e20. G-Protein-Coupled Receptors as Drug Targets (\u003ci\u003eWenyan Miao and Lijun Wu\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e21. Pharmacological Modulation of Ion Channels for the Treatment of Chronic Pain (\u003ci\u003eYi Liu and Ning Qin\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e22. Targeting the mTOR Pathway for Tumor Therapeutics (\u003ci\u003eWei Chen\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003e23. HIV-1 Protease Inhibitors as Antiretroviral Agents (\u003ci\u003eSergei V. Gulnik, Elena Afonina, and Michael Eissenstat\u003c\/i\u003e).\u003c\/p\u003e \u003cp\u003eINDEX.\u003c\/p\u003e  \"The description of each topic is clear, well organized and informative, making the book a useful or even essential high-level handbook.\" (\u003ci\u003eChemMedChem,\u003c\/i\u003e November 2010)\u003cbr\u003e \u003cbr\u003e  \u003cb\u003eChuang Lu, PhD\u003c\/b\u003e, is the Associate Director in the Drug Safety and Disposition Department of Millennium Pharmaceuticals. His current research interests include drug-metabolizing enzymes, drug–drug interaction, and in vitro–in vivo correlation.  \u003cp\u003e\u003cb\u003eAlbert P. Li, PhD\u003c\/b\u003e, is the President and CEO of In Vitro ADMET Laboratories, LLC and Advanced Pharmaceutical Sciences, Inc., and the cofounder, Chairman, and CSO of the ADMET Group. His experience spans over twenty-five years in the drug development industry, with over 150 publications. He is the editor of several books, including \u003ci\u003eDrug–Drug Interactions in Pharmaceutical Development\u003c\/i\u003e, published by Wiley.\u003c\/p\u003e  The science and applied approaches of enzyme inhibition in drug discovery and development  \u003cp\u003eOffering a unique approach that includes both the pharmacologic and pharmaco-kinetic aspects of enzyme inhibition, \u003ci\u003eEnzyme Inhibition in Drug Discovery and Development\u003c\/i\u003e examines the scientific concepts and experimental approaches related to enzyme inhibition as applied in drug discovery and drug development.\u003c\/p\u003e \u003cp\u003eWith chapters written by over fifty leading experts in their fields, \u003ci\u003eEnzyme Inhibition in Drug Discovery and Development\u003c\/i\u003e fosters a cross-fertilization of pharmacology, drug metabolism, pharmacokinetics, and toxicology by understanding the \"good\" inhibitions—desirable pharmacological effects—and \"bad\" inhibitions—drug–drug interactions and toxicity. The book discusses:\u003c\/p\u003e \u003cul\u003e \u003cli\u003e \u003cp\u003eThe drug discovery process, including drug discovery strategy, medicinal chemistry, analytical chemistry, drug metabolism, pharmacokinetics, and safety biomarker assessment\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe manipulations of drug metabolizing enzymes and transporters as well as the negative consequences, such as drug–drug interactions\u003c\/p\u003e \u003c\/li\u003e \u003cli\u003e \u003cp\u003eThe inhibition of several major drug target pathways, such as the GPCR pathway, the NFkB pathway, and the ion channel pathway\u003c\/p\u003e \u003c\/li\u003e \u003c\/ul\u003e \u003cp\u003eThrough this focused, single-source reference on the fundamentals of drug discovery and development, researchers in drug metabolism and pharmacokinetics (DMPK) will learn and appreciate target biology in drug discovery; discovery biologists and medicinal chemists will also broaden their understanding of DMPK.\u003c\/p\u003e","brand":"Wiley","offers":[{"title":"Default Title","offer_id":47989149008101,"sku":"NP9780470281741","price":251.95,"currency_code":"USD","in_stock":false}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/1842\/7735\/files\/9780470281741.jpg?v=1761782993","url":"https:\/\/k12savings.com\/es\/products\/enzyme-inhibition-in-drug-discovery-and-development-isbn-9780470281741","provider":"K12savings","version":"1.0","type":"link"}